Compliance Radar

Who was sanctioned, and for what?

Fines, court rulings and incidents from Europe, North America, Latin America, Asia-Pacific, Middle East and Africa: 2,207 cases from 44 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.

Chemicals and pharmaceuticals Teva Pharmaceutical Industries (Teva-Gruppe) Clear all filters

1case from 1 jurisdiction

€462.6mTotal of monetary amounts

€462.6mLargest single case: Teva Pharmaceutical Industries (Teva-Gruppe)

€462.6mMedian per case with an amount

Click a bar to drill down one level.

by amount by number of cases

Where?

by region

All jurisdictions

EU €462.6m 100 % · 1 case

What for?

by area of law

All areas of law

Competition law €462.6m 100 % · 1 case

Who?

by company

When?

per year, by date of decision

Trend
Period	Cases	Total
2024	1	€462.6m
2025	0	–
2026	0	–

1 case

Newest first Highest amounts

31 Oct 2024 Teva Pharmaceutical Industries (Teva-Gruppe)EU: 462.6 million EUR against Teva for patent misuse and disparaging a competing medicine EU levelAbuse of market power €462.6m

Teva abused its dominant position for the MS medicine Copaxone: it artificially extended patent protection by filing staggered divisional applications with the EPO and strategically withdrawing them, and spread misleading statements about an authorised competing product among physicians and decision-makers. Seven Member States were affected over periods of four to nine years.

What organisations can take from it

Communications by sales representatives and medical affairs about competing products must be substantiated and objective; patent strategies of dominant companies require competition law review.

Relevance to training and awareness

Disparaging statements about competing products to healthcare professionals

Authority / court: Europäische Kommission
Area of law: Competition law · Abuse of market power
Legal basis: Art. 102 AEUV
Action: Fine
Status of proceedings: unknown
Sector: Chemicals and pharmaceuticals
Employees: 10,000 or more

Sources

Commission fines Teva €462.6 million over misuse of the patent system and disparagement (IP/24/5581) Press release of an authority

Checked against the official source on 28 Sep 2026 · Version 2 · Direct link

Report an error

How the radar is compiled

Official sources only

Every case is based on a decision, press release or database of an authority or a court. Press and law-firm reports count at most as additional references.

Four-eyes check

Whoever enters a case may not approve it. A second, independent check compares company, date, amount and area of law with the source. Only then is the case published.

Comparable amounts

Amounts are converted at the ECB reference rate on the day of the decision. Each case also shows the original amount.

Corrections on record

A correction is a new version that is checked again. Every change is logged. You can report errors directly on each case.

Case texts are translated from the German original. Where a translation is not yet available, the German text is shown and marked “(German original)”. Names of authorities, laws and companies are given as in the source (company names until they are anonymised).

Company names are anonymised two years after the decision in a case, in line with the practice of many supervisory authorities. The official sources remain linked.

The radar reports on published decisions and is not legal advice. Decisions that are not yet final are marked as such where the status is known.

Embed the radar on your website

Ready for training that actually lands?